4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children

N

National Institute of Child Health, Hungary

Status and phase

Unknown
Phase 3

Conditions

Recurrent Respiratory Papillomatosis

Treatments

Biological: 4-valent HPV vaccine

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01995721
50934

Details and patient eligibility

About

Recurrent respiratory papillomatosis in children caused by HPV 6,11 can be a life threatening condition resulting in surgical interventions. The maturing and disintegrating papillomas are the sources for the subsequent HPV relapses and immunization might slow down or even prevent this ongoing process. After an initial immunological and ear-nose-throat (ENT) assessment children with at least 3 relapses in their patient history will be vaccinated with 4-valent HPV vaccine according to the following schedule: 0., 2., 6. months. It will be followed by an immunological and 3 ENT examinations to assess response to vaccination.

Full description

Enrollment ear-nose-throat (ENT) examination + oesophagoscopy immunological assessment assessment of selected humoral (antibodies) and cellular immune response parameters(INF gamma and granzyme B testing) in vitro and in vivo stimulation of PMBCs with the HPV-4 vaccine Immunization with 4-valent HPV vaccine at 0,2,6 months Follow up 1 month after 3rd vaccine dose - immunological assessment (same tests as in the enrollment phase) 6, 12 and 18 months after the 3rd vaccine dose - ENT + oesophagoscopy

Enrollment

20 estimated patients

Sex

All

Ages

1 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • respiratory papillomatosis
  • at least 3 relapses in patient history
  • HPV 6 and/or 11 positive papillomas
  • able to mount neutralizing antibodies

Exclusion criteria

  • other chronic underlying condition
  • other HPV type
  • no antibody response

Trial design

20 participants in 1 patient group

4-valent HPV vaccine
Experimental group
Description:
4-valent HPV vaccine administered in months 0., 2., 6.
Treatment:
Biological: 4-valent HPV vaccine

Trial contacts and locations

0

Loading...

Central trial contact

Zsofia Meszner, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems